Specialties

Cardiovascular outcomes often dominate discussions about GLP-1 receptor agonists, but what about nerve health? Growing interest in GLP-1 diabetic neuropathy reflects a broader shift toward understanding microvascular complications beyond heart disease. While medications such as semaglutide (Ozempic), dulaglutide (Trulicity), and liraglutide (Victoza) have proven cardiovascular benefits, their potential influence on …

In 2026, diabetic retinopathy screening is entering a new era driven by artificial intelligence, tele-retinal imaging, and smarter integration into primary care workflows. Despite improved glucose monitoring and widespread use of CGM systems, diabetic retinopathy remains a leading cause of preventable blindness in adults with diabetes. So how can clinicians …

Changes in resting heart rate with GLP-1 receptor agonists have become an important topic in diabetes and cardiometabolic care. As glucagon-like peptide-1 receptor agonists such as semaglutide, liraglutide, and dulaglutide gain widespread use, clinicians often notice a modest rise in resting heart rate. Should this increase raise concern, especially in …

The link between metabolism and reproduction is gaining attention, especially as questions about GLP-1 therapy and male fertility begin to surface in clinical practice. For years, male fertility evaluations focused mainly on hormones and anatomy. However, what if the root problem starts with metabolic health? Obesity and insulin resistance are …

Patients using GLP-1 receptor agonists are reporting something unexpected: less joint and musculoskeletal pain. As interest grows in how GLP-1 therapies may affect chronic pain, clinicians are asking an important question. Are these improvements simply the result of weight loss, or do GLP-1 medications have direct anti-inflammatory and neuromodulatory effects? …

Concerns about GLP-1 pancreatic cancer risk have circulated for more than a decade. When glucagon-like peptide-1 receptor agonists first entered the market, early post-marketing reports and small observational studies raised alarms about pancreatitis and possible malignancy. As a result, clinicians and patients questioned the long-term safety of agents such as …

The potential link between GLP-1 therapies and atrial fibrillation is drawing increasing clinical interest as cardiometabolic care continues to evolve. Patients with type 2 diabetes face a significantly higher risk of atrial fibrillation, yet GLP-1 receptor agonists are rarely discussed in rhythm management conversations. Could medications such as semaglutide (Ozempic), …

GLP-1 receptor agonists are transforming diabetes and obesity care. However, as more women of reproductive age use medications like semaglutide, liraglutide, and tirzepatide, questions about how GLP-1 therapies affect fertility and pregnancy are becoming increasingly common. Can patients conceive safely while taking these agents? Do they improve ovulation in women …

A patient’s A1C can look acceptable on paper while everything else is quietly heading in the wrong direction. Cardiovascular risk is rising, kidney function is slipping, and the patient keeps missing follow-up visits because of cost, transportation, or work constraints. Most clinicians have seen this scenario play out, even when …

For many patients, antipsychotic medications are life-changing, even life-saving. Yet the same treatments that stabilize mood and thought can quietly drive weight gain, insulin resistance, and rising cardiometabolic risk. Over time, this unintended consequence places patients with serious mental illness at a much higher risk for obesity, type 2 diabetes, …